Bridgewater, N.J.’s Aegerion Pharmaceuticals withdrew an IPO that the company expected to raise as much as $80.5 million, citing “market conditions.” The company’s withdrawal statement is here. The company had filed to go public back in March.
Aegerion is developing drugs that lower cholesterol and trigyceride levels by limiting production of the substances in the liver. Like other specialty-pharmaceutical companies, the company doesn’t develop its own drugs, and instead acquires cast-offs from other companies. I wrote about its IPO plans here.
[aditude-amp id="flyingcarpet" targeting='{"env":"staging","page_type":"article","post_id":19490,"post_type":"story","post_chan":"none","tags":null,"ai":false,"category":"none","all_categories":"business,","session":"A"}']VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn More